Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Palisade Bio (Nasdaq: PALI) will present virtually at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palisade Bio (Nasdaq: PALI) will present virtually at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation runs 12:40 PM–1:10 PM ET in Track 3 and will be webcast live. Management will also hold one-on-one in-person meetings with qualified investors. A replay will be archived for a limited time on the company’s Investors Events page at palisadebio.com.
Details
News Market Reaction – PALI
On Feb 5, the day this news came out, PALI closed 5.06% below the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Q3 2025 operating expenses
- $2.9 million
- Down from $3.6 million in prior-year quarter
- Post-quarter equity offering
- $138 million
- Gross proceeds from underwritten offering closed October 2, 2025
- Cash and equivalents
- $5.2 million
- Balance at September 30, 2025 per Q3 2025 10-Q
- IBD Ventures investment
- $500,000
- Strategic equity investment commitment to advance PALI-2108
- Schedule 13G stake
- 9,163,990 shares (6.0%)
- Franklin Advisers, Inc. voting and dispositive power as of Dec 31, 2025
- S-8 registered shares
- 236,557 shares
- 2021 Equity Incentive Plan and ESPP registration on November 12, 2025
- S-3 shelf shares
- 988,872 shares
- Block listed in S-3 shelf registration filed August 15, 2025
- Shares outstanding
- 149,003,210 shares
- Common stock outstanding as of November 5, 2025
Historical Context
-
Added leading global IBD experts to Clinical Advisory Board for PALI-2108.
-
Two PALI-2108 abstracts accepted for major inflammatory bowel disease meetings.
-
Strategic equity investment up to $500,000 from Crohn’s & Colitis Foundation.
-
Japanese composition-of-matter patent granted for lead candidate PALI-2108.
-
Appointed VP, Clinical Development with extensive Phase 2/3 trial experience.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pde4 inhibitor prodrugs medical
terminal ileum medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET
Access the webcast here
Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026.
The Company’s virtual presentation is scheduled for Thursday, February 26, 2026, from 12:40 PM to 1:10 PM ET in Track 3.
In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and will be archived for a limited time.
About PALI-2108
PALI-2108 is a once-daily, oral prodrug designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon through local bacterial bioactivation. The prodrug is pharmacologically inactive until it reaches the lower intestine, where bacterial enzymes convert it into the active PDE4 inhibitor at sites of inflammation and fibrosis. This targeted activation strategy prevents absorption in the upper gut, enables sustained local exposure with controlled systemic distribution, and is engineered to reduce peak plasma levels, thereby improving the overall therapeutic index and reducing tolerability limitations such as diarrhea, nausea and headache that have constrained systemic PDE4 inhibitors.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. In a recently reported Phase 1b trial, PALI-2108 achieved a
Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is completing early studies in FSCD to further characterize PALI-2108’s safety, pharmacology and potential therapeutic benefit across inflammatory bowel disease indications. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.